Literature DB >> 8852497

Verapamil deleterious effects in chronic renal failure.

C Váquez1, A Huelmos, E Alegría, P Errasti, A Purroy.   

Abstract

Three hypertensive patients with chronic renal failure treated with slow-release verapamil at the recommended doses for high blood pressure experienced acute deleterious effects shortly after treatment (6 h to 3 days). Patients developed slow cardiac rhythms (junctional bradycardia or atrial fibrillation), hypotension and hyperkalemia. Consequently they also had oliguria and worsening of the renal function. Inotropic support, fluid therapy and potassium-lowering measures were able to restore the renal function and sinus rhythm after 10-12 h. Only 7 similar cases have been described so far. It is suggested that slow-release formulations of verapamil must be used with caution in hypertensive patients with impaired renal function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8852497     DOI: 10.1159/000188913

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  2 in total

1.  Bradycardia, Renal Failure, Atrioventricular Nodal Blockade, Shock, and Hyperkalemia Syndrome as a Clinical Profile Leading to the Diagnosis of Transthyretin Amyloidosis: A Report of Two Cases.

Authors:  Koji Takahashi; Tomoki Sakaue; Shigeki Uemura; Takafumi Okura; Shuntaro Ikeda
Journal:  Cureus       Date:  2022-05-29

2.  Cardiotoxicity of verapamil in renal failure: a case report and review of the literature.

Authors:  Praveen P Jadhav; Suresh Bohra
Journal:  Cases J       Date:  2009-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.